BioSpace News Archive

Virtue® SEB is expected to become a flagship therapeutic product for Terumo and will strengthen its broad US and global portfolio of interventional solutions

Bioz, Inc., a Silicon Valley AI data company, is proud to announce a new partnership with the world leader in the discovery and production of enzymes for molecular biology applications: New England Biolabs®.

Amarantus Bioscience Holdings, Inc. announced that subsidiary MANF Therapeutics was issued U.S. Patent No. 10,195,251 entitled ‘Methods of Treatment for Retinal Diseases Using MANF and CDNF’ that covers the use of mesencephalic astrocyte-derived neurotrophic factor or cerebral dopamine neurotrophic factor as a treatment for various ophthalmic disorders, including inherited retinal disorders, age-related macular degeneration and glaucoma.

Clinical Ink is pleased to announce that Jonathan Andrus, chief business officer at Clinical Ink, has been invited to be a panelist in a public meeting hosted by the Duke-Margolis Center for Health Policy on July 17, 2019, in Washington, D.C. The workshop, convened under a cooperative agreement with the FDA, will discuss opportunities to improve the implementation of risk-based monitoring (RBM) in clinical investigations.

Pyoderma Gangraenosum is a debilitating, rare autoimmune disease marked by large, painful skin ulcers

Research findings may provide deeper understanding on the role of genes that can contribute to development of Hypophosphatasia

Texas-based Savara tried to put a positive spin on the trial and pointed to positive secondary endpoints but it wasn’t enough to please investors.

The Laboratory for Genomics Research will be funded by GSK up to $67 million over the five-year period and will include space for 24 full-time university employees and up to 14 full-time GSK staffers.

With Backing from Google, J&J and Others, BlackThorn Raises $76 Million Series B.

A substantial number of blood cancer patients could make more informed decisions on their treatment if more information becomes available for them and their treating physicians.